Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells 2,686 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYCGet Free Report) CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. The trade was a 7.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Travis Alvin Thompson also recently made the following trade(s):

  • On Thursday, January 2nd, Travis Alvin Thompson sold 1,750 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $14.09, for a total transaction of $24,657.50.
  • On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16.

Bicycle Therapeutics Stock Down 0.1 %

Shares of Bicycle Therapeutics stock opened at $14.88 on Tuesday. The firm has a market cap of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The company’s fifty day simple moving average is $19.27 and its two-hundred day simple moving average is $21.86.

Bicycle Therapeutics (NASDAQ:BCYCGet Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same quarter last year, the firm earned ($1.26) EPS. The company’s revenue was down 50.0% on a year-over-year basis. As a group, sell-side analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of BCYC. Natixis Advisors LLC purchased a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth about $261,000. TD Asset Management Inc lifted its position in shares of Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after purchasing an additional 42,200 shares during the period. Renaissance Technologies LLC lifted its position in shares of Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after purchasing an additional 161,100 shares during the period. L & S Advisors Inc lifted its position in shares of Bicycle Therapeutics by 16.1% in the 2nd quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after purchasing an additional 8,075 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth about $206,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on BCYC. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. HC Wainwright reduced their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a report on Monday, December 16th. B. Riley reduced their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Finally, Stephens assumed coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.25.

View Our Latest Analysis on Bicycle Therapeutics

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Further Reading

Insider Buying and Selling by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.